Short Interest in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Decreases By 13.7%

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) was the recipient of a large decline in short interest in March. As of March 15th, there was short interest totalling 3,400,000 shares, a decline of 13.7% from the February 28th total of 3,940,000 shares. Approximately 6.2% of the company’s shares are sold short. Based on an average daily volume of 781,700 shares, the short-interest ratio is presently 4.3 days.

Insiders Place Their Bets

In other news, insider Tsveta Milanova sold 2,804 shares of Agios Pharmaceuticals stock in a transaction on Monday, January 6th. The stock was sold at an average price of $32.18, for a total transaction of $90,232.72. Following the transaction, the insider now owns 18,906 shares in the company, valued at approximately $608,395.08. The trade was a 12.92 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 4.93% of the company’s stock.

Institutional Investors Weigh In On Agios Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in AGIO. GF Fund Management CO. LTD. acquired a new position in Agios Pharmaceuticals during the fourth quarter valued at approximately $39,000. Frazier Life Sciences Management L.P. grew its stake in Agios Pharmaceuticals by 2.5% in the 4th quarter. Frazier Life Sciences Management L.P. now owns 1,069,754 shares of the biopharmaceutical company’s stock valued at $35,152,000 after buying an additional 25,600 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Agios Pharmaceuticals by 8.5% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 122,835 shares of the biopharmaceutical company’s stock worth $4,036,000 after acquiring an additional 9,606 shares during the period. Voloridge Investment Management LLC lifted its position in Agios Pharmaceuticals by 2.1% during the 4th quarter. Voloridge Investment Management LLC now owns 200,481 shares of the biopharmaceutical company’s stock worth $6,588,000 after acquiring an additional 4,082 shares during the last quarter. Finally, Squarepoint Ops LLC bought a new stake in Agios Pharmaceuticals during the fourth quarter valued at about $5,337,000.

Analyst Ratings Changes

Several research firms have weighed in on AGIO. HC Wainwright began coverage on Agios Pharmaceuticals in a research note on Monday, February 24th. They set a “buy” rating and a $58.00 target price on the stock. Royal Bank of Canada boosted their price objective on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a research report on Tuesday, December 10th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Wednesday, December 18th. StockNews.com lowered shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, February 14th. Finally, Scotiabank upped their price target on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a research note on Monday, December 9th. One research analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, Agios Pharmaceuticals has a consensus rating of “Hold” and an average price target of $56.57.

Agios Pharmaceuticals Trading Down 2.6 %

Agios Pharmaceuticals stock opened at $27.71 on Friday. Agios Pharmaceuticals has a 1-year low of $26.66 and a 1-year high of $62.58. The firm’s fifty day simple moving average is $32.73 and its 200-day simple moving average is $40.40. The company has a market capitalization of $1.59 billion, a P/E ratio of 2.44 and a beta of 0.90.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. On average, equities research analysts predict that Agios Pharmaceuticals will post -6.85 earnings per share for the current year.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.